The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Marketwire

Trimel Pharmaceuticals Corporation Announces Appointment of New Director

Tuesday, April 30, 2013

Trimel Pharmaceuticals Corporation Announces Appointment of New Director

17:50 EDT Tuesday, April 30, 2013

TORONTO, ONTARIO--(Marketwired - April 30, 2013) - Trimel Pharmaceuticals Corporation (TSX:TRL) is pleased to announce the appointment of Dr. Lorne Tyrrell to its Board of Directors.

Dr. Tyrrell has had a distinguished medical career, with numerous research achievements particularly in the field of virology and antiviral research. Dr. Tyrrell is presently a professor in the Department of Medical Microbiology and Immunology at the University of Alberta Faculty of Medicine and Dentistry and is a founding director of the Li Ka Shing Institute of Virology at the University of Alberta. Dr. Tyrrell is a recipient of over forty awards and honours, including the Order of Canada and Alberta Order of Excellence, and is a member of the Canadian Medical Hall of Fame. Additionally, Dr. Tyrrell has been active in numerous business ventures in the pharmaceutical industry and has previously served, or is currently serving, on the boards of directors of other publicly traded companies.

"The addition of Dr. Tyrrell to the Board of Directors is a very positive event for Trimel," said Bruce Brydon, Chairman of the Board. "With his long and esteemed career in medical research and deep pool of scientific knowledge, we believe he is an excellent addition to the Board and will help to further Trimel's development and growth. We are extremely excited to move forward with Dr. Tyrrell as part of the Board."

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been filed with the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Contact Information:
Trimel Pharmaceuticals Corporation
Kenneth G. Howling
Chief Financial Officer
(416) 679-0536
ir@trimelpharmaceuticals.com
www.trimelpharmaceuticals.com

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

The Globe at your Workplace
Our Company
Customer Service
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections